4 things to know about Pfizer’s $5.2 billion acquisition target Anacor
May 16, 2016 at 14:48 PM EDT
Pfizer is paying billions for a company whose flagship product has not yet been approved.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.